Literature DB >> 20157310

A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication.

M Arcos-Burgos1, M Jain, M T Acosta, S Shively, H Stanescu, D Wallis, S Domené, J I Vélez, J D Karkera, J Balog, K Berg, R Kleta, W A Gahl, E Roessler, R Long, J Lie, D Pineda, A C Londoño, J D Palacio, A Arbelaez, F Lopera, J Elia, H Hakonarson, S Johansson, P M Knappskog, J Haavik, M Ribases, B Cormand, M Bayes, M Casas, J A Ramos-Quiroga, A Hervas, B S Maher, S V Faraone, C Seitz, C M Freitag, H Palmason, J Meyer, M Romanos, S Walitza, U Hemminger, A Warnke, J Romanos, T Renner, C Jacob, K-P Lesch, J Swanson, A Vortmeyer, J E Bailey-Wilson, F X Castellanos, M Muenke.   

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) has a very high heritability (0.8), suggesting that about 80% of phenotypic variance is due to genetic factors. We used the integration of statistical and functional approaches to discover a novel gene that contributes to ADHD. For our statistical approach, we started with a linkage study based on large multigenerational families in a population isolate, followed by fine mapping of targeted regions using a family-based design. Family- and population-based association studies in five samples from disparate regions of the world were used for replication. Brain imaging studies were performed to evaluate gene function. The linkage study discovered a genome region harbored in the Latrophilin 3 gene (LPHN3). In the world-wide samples (total n=6360, with 2627 ADHD cases and 2531 controls) statistical association of LPHN3 and ADHD was confirmed. Functional studies revealed that LPHN3 variants are expressed in key brain regions related to attention and activity, affect metabolism in neural circuits implicated in ADHD, and are associated with response to stimulant medication. Linkage and replicated association of ADHD with a novel non-candidate gene (LPHN3) provide new insights into the genetics, neurobiology, and treatment of ADHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157310     DOI: 10.1038/mp.2010.6

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  103 in total

1.  FLRT proteins are endogenous latrophilin ligands and regulate excitatory synapse development.

Authors:  Matthew L O'Sullivan; Joris de Wit; Jeffrey N Savas; Davide Comoletti; Stefanie Otto-Hitt; John R Yates; Anirvan Ghosh
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 2.  Annual Research Review: Discovery science strategies in studies of the pathophysiology of child and adolescent psychiatric disorders--promises and limitations.

Authors:  Yihong Zhao; F Xavier Castellanos
Journal:  J Child Psychol Psychiatry       Date:  2016-01-06       Impact factor: 8.982

3.  The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population.

Authors:  Geurt van de Glind; Katelijne Van Emmerik-van Oortmerssen; Pieter Jan Carpentier; Frances R Levin; Maarten W J Koeter; Csaba Barta; Sharlene Kaye; Arvid Skutle; Johan Franck; Maija Konstenius; Eli-Torild Bu; Franz Moggi; Geert Dom; Zolt Demetrovics; Mélina Fatséas; Arild Schillinger; Máté Kapitány-Fövény; Sofie Verspreet; Andrea Seitz; Brian Johnson; Stephen V Faraone; J Antoni Ramos-Quiroga; Steve Allsop; Susan Carruthers; Robert A Schoevers; Wim van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2013-09-11       Impact factor: 4.035

4.  From the black widow spider to human behavior: Latrophilins, a relatively unknown class of G protein-coupled receptors, are implicated in psychiatric disorders.

Authors:  Ariel F Martinez; Maximilian Muenke; Mauricio Arcos-Burgos
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-11-12       Impact factor: 3.568

5.  Knockout of latrophilin-3 in Sprague-Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine, and disrupted dopamine markers.

Authors:  Samantha L Regan; Jillian R Hufgard; Emily M Pitzer; Chiho Sugimoto; Yueh-Chiang Hu; Michael T Williams; Charles V Vorhees
Journal:  Neurobiol Dis       Date:  2019-06-06       Impact factor: 5.996

6.  Latrophilin 1 and its endogenous ligand Lasso/teneurin-2 form a high-affinity transsynaptic receptor pair with signaling capabilities.

Authors:  John-Paul Silva; Vera G Lelianova; Yaroslav S Ermolyuk; Nickolai Vysokov; Paul G Hitchen; Otto Berninghausen; M Atiqur Rahman; Alice Zangrandi; Sara Fidalgo; Alexander G Tonevitsky; Anne Dell; Kirill E Volynski; Yuri A Ushkaryov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-01       Impact factor: 11.205

7.  An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility.

Authors:  Ariel F Martinez; Yu Abe; Sungkook Hong; Kevin Molyneux; David Yarnell; Heiko Löhr; Wolfgang Driever; Maria T Acosta; Mauricio Arcos-Burgos; Maximilian Muenke
Journal:  Biol Psychiatry       Date:  2016-07-14       Impact factor: 13.382

8.  Deletion in the N-terminal half of olfactomedin 1 modifies its interaction with synaptic proteins and causes brain dystrophy and abnormal behavior in mice.

Authors:  Naoki Nakaya; Afia Sultana; Jeeva Munasinghe; Aiwu Cheng; Mark P Mattson; Stanislav I Tomarev
Journal:  Exp Neurol       Date:  2013-10-02       Impact factor: 5.330

9.  Influence of a latrophilin 3 (LPHN3) risk haplotype on event-related potential measures of cognitive response control in attention-deficit hyperactivity disorder (ADHD).

Authors:  Andreas J Fallgatter; Ann-Christine Ehlis; Thomas Dresler; Andreas Reif; Christian P Jacob; Mauricio Arcos-Burgos; Maximilian Muenke; Klaus-Peter Lesch
Journal:  Eur Neuropsychopharmacol       Date:  2012-12-12       Impact factor: 4.600

10.  SPOCK3, a risk gene for adult ADHD and personality disorders.

Authors:  Heike Weber; Claus-Jürgen Scholz; Christian P Jacob; Julia Heupel; Sarah Kittel-Schneider; Angelika Erhardt; Susanne Hempel; Brigitte Schmidt; Tilman Kiel; Alexandra Gessner; Klaus-Peter Lesch; Andreas Reif
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11-29       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.